129 related articles for article (PubMed ID: 17661718)
21. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
22. Treatment options for hepatocellular carcinoma.
Sandhu DS; Tharayil VS; Lai JP; Roberts LR
Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):81-92. PubMed ID: 19072372
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search.
Moribe T; Iizuka N; Miura T; Stark M; Tamatsukuri S; Ishitsuka H; Hamamoto Y; Sakamoto K; Tamesa T; Oka M
Int J Oncol; 2008 Nov; 33(5):949-58. PubMed ID: 18949357
[TBL] [Abstract][Full Text] [Related]
24. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
25. Proteomics for the early detection and treatment of hepatocellular carcinoma.
Feng JT; Shang S; Beretta L
Oncogene; 2006 Jun; 25(27):3810-7. PubMed ID: 16799622
[TBL] [Abstract][Full Text] [Related]
26. Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures.
Braconi C; Meng F; Swenson E; Khrapenko L; Huang N; Patel T
Cancer; 2009 Aug; 115(16):3738-48. PubMed ID: 19514085
[TBL] [Abstract][Full Text] [Related]
27. Molecular prediction of early recurrence after resection of hepatocellular carcinoma.
Yoshioka S; Takemasa I; Nagano H; Kittaka N; Noda T; Wada H; Kobayashi S; Marubashi S; Takeda Y; Umeshita K; Dono K; Matsubara K; Monden M
Eur J Cancer; 2009 Mar; 45(5):881-9. PubMed ID: 19167881
[TBL] [Abstract][Full Text] [Related]
28. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population.
Cucchetti A; Piscaglia F; Caturelli E; Benvegnù L; Vivarelli M; Ercolani G; Cescon M; Ravaioli M; Grazi GL; Bolondi L; Pinna AD
Ann Surg Oncol; 2009 Feb; 16(2):413-22. PubMed ID: 19034578
[TBL] [Abstract][Full Text] [Related]
29. Molecular pathogenesis of hepatocellular carcinoma.
McKillop IH; Moran DM; Jin X; Koniaris LG
J Surg Res; 2006 Nov; 136(1):125-35. PubMed ID: 17023002
[TBL] [Abstract][Full Text] [Related]
30. Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma.
Minagawa H; Honda M; Miyazaki K; Tabuse Y; Teramoto R; Yamashita T; Nishino R; Takatori H; Ueda T; Kamijo K; Kaneko S
Biochem Biophys Res Commun; 2008 Feb; 366(1):186-92. PubMed ID: 18060859
[TBL] [Abstract][Full Text] [Related]
31. Comparative functional genomics for identifying models of human cancer.
Lee JS; Grisham JW; Thorgeirsson SS
Carcinogenesis; 2005 Jun; 26(6):1013-20. PubMed ID: 15677630
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling of non-small-cell lung cancer.
Lacroix L; Commo F; Soria JC
Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
[TBL] [Abstract][Full Text] [Related]
33. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice.
Katzenellenbogen M; Mizrahi L; Pappo O; Klopstock N; Olam D; Jacob-Hirsch J; Amariglio N; Rechavi G; Domany E; Galun E; Goldenberg D
Mol Cancer Res; 2007 Nov; 5(11):1159-70. PubMed ID: 18025261
[TBL] [Abstract][Full Text] [Related]
35. [Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma].
Moon JI; Kim JM; Jung GO; Chun JM; Choi GS; Park JB; Kwon CH; Kim SJ; Jo JW
Korean J Hepatol; 2008 Jun; 14(2):185-96. PubMed ID: 18617766
[TBL] [Abstract][Full Text] [Related]
36. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches.
Breuhahn K; Gores G; Schirmacher P
Hepatology; 2011 Jun; 53(6):2112-21. PubMed ID: 21433041
[TBL] [Abstract][Full Text] [Related]
37. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma.
Sakamoto M; Mori T; Masugi Y; Effendi K; Rie I; Du W
Intervirology; 2008; 51 Suppl 1():42-5. PubMed ID: 18544947
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
Hussain K; El-Serag HB
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):123-38. PubMed ID: 19305372
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao M; Qiu LW; Zong L; Wu W; Wu XH; Yao DB; Meng XY
Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):288-95. PubMed ID: 18522884
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma in viral hepatitis: improving standard therapy.
Masuzaki R; Yoshida H; Tateishi R; Shiina S; Omata M
Best Pract Res Clin Gastroenterol; 2008; 22(6):1137-51. PubMed ID: 19187872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
